EVA Pharma, DNA Script, and Quantoom Biosciences Partner on mRNA Vaccine Production

• EVA Pharma, DNA Script, and Quantoom Biosciences have signed a Memorandum of Understanding (MoU) to establish a digital-to-biologics mRNA production platform in Egypt.

• The collaboration aims to produce 100 million RNA-based vaccine doses annually, supporting Africa CDC’s goal of 60% local vaccine production by 2040.

EVA Pharma, an Egyptian pharmaceutical company, has partnered with France’s DNA Script and Belgium’s Quantoom Biosciences to establish Africa’s first end-to-end mRNA production platform. The partnership was formalised through a Memorandum of Understanding (MoU) signed during the 2nd Vaccine and Other Health Products Manufacturing Forum for African Union Member States, held in Cairo.

The initiative focuses on developing and manufacturing mRNA and saRNA-based vaccines and therapeutics, addressing both human and animal health needs. The production platform will integrate DNA Script’s enzymatic DNA synthesis, Quantoom’s mRNA synthesis and formulation technologies, and EVA Pharma’s vaccine development, GMP sterile manufacturing expertise and commercialization capabilities. The goal is to localise production and enhance Africa’s ability to respond rapidly to infectious disease outbreaks and routine immunisation demands.

The collaboration is set to deliver 100 million doses of RNA-based vaccines annually, advancing Africa CDC’s objective of achieving 60% local vaccine production by 2040. Additionally, it aligns with Egypt’s ambition to produce 385 million vaccine doses per year by 2030, strengthening the region’s biopharmaceutical autonomy and public health resilience.

Dr. Riad Armanious, CEO of EVA Pharma, emphasised the project’s significance, stating, “Our cross-continental collaboration will empower patients with next-generation, scalable, and versatile solutions that transform what once took years into a process achievable in weeks.”

Marc Montserrat, CEO of DNA Script, stated: “Our collaboration with EVA Pharma and Univercells-Quantoom advances enzymatic DNA synthesis to accelerate vaccine development and delivery. By reducing DNA production time and enabling longer, more complex sequences, the partnership ensures faster access to innovative vaccines for those at highest risk during epidemics.”

José Castillo, CEO of Quantoom Biosciences, added: “This collaboration demonstrates the power of cross-border expertise, advancing RNA technologies and improving global health equity by making life-saving vaccines and therapeutics accessible to underserved populations.”